SCHEMBL19744060

SCHEMBL19744060

Cc1ccc2c(N=C3NC(=Nc4c(N5CCN(C)CC5)nn5c(C)c(C)ccc45)C(N)=CC3=N)c(N3CCN(C)CC3)nn2c1C

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 4/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17851654 1.00 HRH4 (0.31) HRH4
SCHEMBL19680462 1.00 HRH4 (0.31) HRH4
SCHEMBL26465502 0.92 PDE10A (0.30)
SCHEMBL26095472 0.92 PDE10A (0.30)
SCHEMBL19680469 0.92 PDE10A (0.30)
SCHEMBL19744239 0.91 PDE10A (0.30)
SCHEMBL17851638 0.91 PDE10A (0.30)
SCHEMBL19680464 0.91 PDE10A (0.30)
SCHEMBL19743689 0.89 PIK3CA (0.34)
SCHEMBL19680460 0.89 PIK3CA (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11896700-B2 Process for treating keratin fibers using an anhydrous composition comprising a compound of azomethine type comprising two pyrazolopyridine units and an aqueous composition L'OREAL (FR) 2024-02-13 US claimed
US-20230137804-A1 PROCESS FOR TREATING KERATIN FIBERS USING AN ANHYDROUS COMPOSITION COMPRISING A COMPOUND OF AZOMETHINE TYPE COMPRISING TWO PYRAZOLOPYRIDINE UNITS AND AN AQUEOUS COMPOSITION L'OREAL (FR) 2023-05-04 US claimed
EP-3474815-B1 PROCESS FOR TREATING KERATIN FIBERS USING AN ANHYDROUS COMPOSITION COMPRISING A COMPOUND OF AZOMETHINE TYPE COMPRISING TWO PYRAZOLOPYRIDINE UNITS AND AN AQUEOUS COMPOSITION OREAL (FR) 2022-03-16 EP claimed
EP-3474815-A1 PROCESS FOR TREATING KERATIN FIBERS USING AN ANHYDROUS COMPOSITION COMPRISING A COMPOUND OF AZOMETHINE TYPE COMPRISING TWO PYRAZOLOPYRIDINE UNITS AND AN AQUEOUS COMPOSITION L'OREAL (FR) 2019-05-01 EP claimed
WO-2017220676-A1 PROCESS FOR TREATING KERATIN FIBERS USING AN ANHYDROUS COMPOSITION COMPRISING A COMPOUND OF AZOMETHINE TYPE COMPRISING TWO PYRAZOLOPYRIDINE UNITS AND AN AQUEOUS COMPOSITION L'OREAL (FR) 2017-12-28 WO claimed
EP-3474815-B1 PROCESS FOR TREATING KERATIN FIBERS USING AN ANHYDROUS COMPOSITION COMPRISING A COMPOUND OF AZOMETHINE TYPE COMPRISING TWO PYRAZOLOPYRIDINE UNITS AND AN AQUEOUS COMPOSITION OREAL (FR) 2022-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11896700-B2 Process for treating keratin fibers using an anhydrous composition comprising a compound of azomethine type comprising two pyrazolopyridine units and an aqueous composition KRT18, DPYD, CKAP4 HRH4 711/4885
US-20230137804-A1 PROCESS FOR TREATING KERATIN FIBERS USING AN ANHYDROUS COMPOSITION COMPRISING A COMPOUND OF AZOMETHINE TYPE COMPRISING TWO PYRAZOLOPYRIDINE UNITS AND AN AQUEOUS COMPOSITION KRT18, DPYD, CKAP4 HRH4 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.